GFAP and Alzheimer disease: Within the biomarkers that were not specific to AD, findings on plasma GFAP levels stand out because of the early increase at the prodromal stage of MCI‐LB and its strong and consistent correlation with high PiB SUVr across the entire DLB continuum.